Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14806588 | 0.97 | GSK3A (0.33) | GSK3AGSK3BMGLLCASP3 | |
| SCHEMBL19752251 | 0.80 | — | — | |
| SCHEMBL21861833 | 0.80 | — | — | |
| SCHEMBL6850987 | 0.76 | GSK3A (0.44) | GSK3AGSK3BMGLLCASP3ALDH1A1 | |
| SCHEMBL22246111 | 0.67 | CASP3 (0.37) | GSK3AGSK3BMGLLCASP3 | |
| SCHEMBL802733 | 0.67 | ALDH1A1 (0.40) | GSK3AGSK3BMGLLCASP3ALDH1A1 | |
| SCHEMBL24690693 | 0.65 | USP2 (0.32) | — | |
| SCHEMBL22342866 | 0.64 | ALDH1A1 (0.35) | GSK3AGSK3BMGLLCASP3ALDH1A1 | |
| SCHEMBL11414636 | 0.64 | GSK3A (0.35) | GSK3AGSK3BMGLLCASP3ALDH1A1 | |
| SCHEMBL7181082 | 0.64 | GSK3A (0.35) | GSK3AGSK3BMGLLCASP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542063-B1 | USE OF MALEIMIDE SALTS FOR COMBATING PHYTOPATHOGENIC FUNGI | BAYER IP GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2542063-B1 | USE OF MALEIMIDE SALTS FOR COMBATING PHYTOPATHOGENIC FUNGI | BAYER IP GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8410024-B2 | Use of maleimide salts to control phytopathogenic fungi | BAYER CROPSCIENCE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410024-B2 | Use of maleimide salts to control phytopathogenic fungi | BAYER CROPSCIENCE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410024-B2 | Use of maleimide salts to control phytopathogenic fungi | BAYER CROPSCIENCE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2542063-A1 | USE OF MALEIMIDE SALTS FOR CONTROLLING PHYTOPATHOGENIC FUNGI | Bayer Intellectual Property GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-20110245218-A1 | Use of Maleimide Salts to Control Phytopathogenic Fungi | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245218-A1 | Use of Maleimide Salts to Control Phytopathogenic Fungi | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245218-A1 | Use of Maleimide Salts to Control Phytopathogenic Fungi | BAYER CROPSCIENCE AG (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2011107444-A1 | USE OF MALEIMIDE SALTS FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107444-A1 | USE OF MALEIMIDE SALTS FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245218-A1 | Use of Maleimide Salts to Control Phytopathogenic Fungi | MLEC, PMM2, MGAM | GSK3A 1947/4885GSK3B 1898/4885MGLL 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.